Better Therapeutics Inc. (BTTX)

Overview

Better Therapeutics, Inc. is a pioneering force in the realm of prescription digital therapeutics, specifically targeting the root causes of cardiometabolic diseases through a sophisticated application of cognitive behavioral therapy. This innovative approach marks a departure from traditional treatments, focusing instead on employing digital platforms to modify behavior and lifestyle choices that contribute to these conditions. Since its establishment in 2015 and based in San Francisco, California, the company has been at the forefront of developing software-based solutions designed to tackle a wide array of cardiometabolic diseases, including type 2 diabetes, hypertension, and more.

Products and Services

Better Therapeutics, Inc. offers a portfolio of digital therapeutics platforms and is actively developing several clinical candidates to address various cardiometabolic diseases:

• BT-001: This investigational Prescription Digital Therapeutic (PDT) platform is in the lead for Better Therapeutics, targeting the treatment of type 2 diabetes through cognitive behavioral therapy techniques designed to modify behavior and lifestyle choices that affect the disease.
• BT-002: Focused on glycemic control for patients with hypertension, BT-002 integrates into the company's suite of digital therapeutics, emphasizing the role of cognitive behavior modification in managing and potentially reversing the impact of hypertension on diabetes.
• BT-003: Aimed at reducing LDL cholesterol in patients suffering from hyperlipidemia, BT-003 continues the company's focus on addressing cardiometabolic conditions through lifestyle and behavioral changes facilitated by digital interventions.
• BT-004: This candidate explores the potential impacts of digital therapeutic interventions on liver health, specifically targeting patients with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD), marking an innovative step towards treating liver conditions through cognitive behavioral therapy.

In addition to these specific product candidates, Better Therapeutics is dedicated to the broader development and deployment of software-based prescription digital therapeutics for a variety of diseases. Their pipeline also demonstrates a commitment to clinical development candidates intended to treat a range of cardiometabolic diseases, encapsulating conditions such as hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease, among others.